Arsenic trioxide liposome gels for the treatment of psoriasis in mice

References

• Allen, T.M., and Cullis, P.R., 2013. Liposomal drug delivery systems: from concept to clinical applications. Advanced drug delivery reviews, 65 (1), 36–48. doi: 10.1016/j.addr.2012.09.037.
   PubMed Web of Science ®Google Scholar
• Armstrong, A.W., and Read, C., 2020. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA, 323 (19), 1945–1960. doi: 10.1001/jama.2020.4006.
   PubMed Web of Science ®Google Scholar
• Burchacka, E., et al., 2016. New effective azelaic acid liposomal gel formulation of enhanced pharmaceutical bioavailability. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 83, 771–775. doi: 10.1016/j.biopha.2016.07.014.
   PubMed Web of Science ®Google Scholar
• Çağdaş, M., Sezer, A.D., and Bucak, S., 2014. Liposomes as potential drug carrier systems for drug delivery. Application of nanotechnology in drug delivery, 1, 1–50.
   Google Scholar
• Chen, H., et al., 2006. Lipid encapsulation of arsenic trioxide attenuates cytotoxicity and allows for controlled anticancer drug release. Journal of the american chemical society, 128 (41), 13348–13349. doi: 10.1021/ja064864h.
   PubMed Web of Science ®Google Scholar
• Dawoud, M.H., et al., 2019. Insulin mucoadhesive liposomal gel for wound healing: a formulation with sustained release and extended stability using quality by design approach. AAPS pharmscitech, 20 (4), 158. doi: 10.1208/s12249-019-1363-6.
   PubMed Web of Science ®Google Scholar
• Enamandram, M., and Kimball, A.B., 2013. Psoriasis epidemiology: the interplay of genes and the environment. The journal of investigative dermatology, 133 (2), 287–289. doi: 10.1038/jid.2012.434.
   PubMedGoogle Scholar
• Evens, A.M., Tallman, M.S., and Gartenhaus, R.B., 2004. The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leukemia research, 28 (9), 891–900. doi: 10.1016/j.leukres.2004.01.011.
   PubMedGoogle Scholar
• Ge, F., et al., 2016. Arsenic trioxide-based therapy is suitable for patients with psoriasis-associated acute promyelocytic leukemia–A retrospective clinical study. Hematology (Amsterdam, Netherlands), 21 (5), 287–294. doi: 10.1080/10245332.2015.1115586.
   PubMed Web of Science ®Google Scholar
• Guo, M., et al., 2017. HPLC-HG-AFS determination of arsenic species in acute promyelocytic leukemia (APL) plasma and blood cells. Journal of pharmaceutical and biomedical analysis, 145, 356–363. doi: 10.1016/j.jpba.2017.07.001.
   PubMed Web of Science ®Google Scholar
• Hao, X., et al., 2022. Intravenous As2O3 as a promising treatment for psoriasis—an experimental study in psoriasis-like mouse model. Immunopharmacology and immunotoxicology, 44 (6), 935–958. doi: 10.1080/08923973.2022.2093742.
   PubMedGoogle Scholar
• Hendriks, A.G.M., et al., 2013. Efficacy and safety of combinations of first‐line topical treatments in chronic plaque psoriasis: a systematic literature review. Journal of the european academy of dermatology and venereology, 27 (8), 931–951. doi: 10.1111/jdv.12058.
   PubMed Web of Science ®Google Scholar
• Horn, E.J., et al., 2010. Topical corticosteroids in psoriasis: strategies for improving safety. Journal of the european academy of dermatology and venereology, 24 (2), 119–124. doi: 10.1111/j.1468-3083.2009.03358.x.
   PubMed Web of Science ®Google Scholar
• Jindal, S., et al., 2020. Topical delivery of Tacrolimus using liposome containing gel: an emerging and synergistic approach in management of psoriasis. Medical hypotheses, 142, 109838. doi: 10.1016/j.mehy.2020.109838.
   PubMed Web of Science ®Google Scholar
• Kazi, A.G., et al., 2021. Adverse impact of occupational exposure on Laborers of cement industry have scalp psoriasis and Pityriasis amiantacea with deficiency of zinc and selenium: impact of mineral supplement. Environmental science and pollution research international, 28 (48), 68330–68337. doi: 10.1007/s11356-021-15307-1.
   PubMedGoogle Scholar
• Keyhani, M., 2012. Use of arsenic trioxide as a first-line single agent in the treatment of acute promyelocytic leukemia. Journal of clinical oncology, 30 (2), 217–217. doi: 10.1200/JCO.2011.38.7654.
   PubMedGoogle Scholar
• Nakamura, M., and Koo, J., 2020. Safety considerations with combination therapies for psoriasis. Expert opinion on drug safety, 19 (4), 489–498. doi: 10.1080/14740338.2020.1722640.
   PubMedGoogle Scholar
• Parisi, R., et al., 2013. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. The journal of investigative dermatology, 133 (2), 377–385. doi: 10.1038/jid.2012.339.
   PubMed Web of Science ®Google Scholar
• Stewart, T.J., Tong, W., and Whitfeld, M.J., 2018. The associations between psychological stress and psoriasis: a systematic review. International journal of dermatology, 57 (11), 1275–1282. doi: 10.1111/ijd.13956.
   PubMed Web of Science ®Google Scholar
• Torres, T., et al., 2014. Levels of physical activity in patients with severe psoriasis: a cross-sectional questionnaire study. American journal of clinical dermatology, 15 (2), 129–135. doi: 10.1007/s40257-014-0061-0.
   PubMed Web of Science ®Google Scholar
• Wasankar, S.R., Faizi, S.M., and Deshmuk, A.D., 2012. Formulation and development of liposomal gel for topical drug delivery system. International journal of pharmaceutical sciences and research, 3, 4461.
   Google Scholar
• Zhang, J., et al., 2023. Desonide nanoemulsion gel for transdermal absorption drug delivery: pharmacodynamic and safety evaluation. Current drug delivery, 20 (10), 1525–1532. doi: 10.2174/1567201819666220819110128.
   PubMed Web of Science ®Google Scholar
• Zhou, G.B., et al., 2007. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philosophical transactions of the royal society of london. Series B, biological sciences, 362 (1482), 959–971. doi: 10.1098/rstb.2007.2026.
   PubMed Web of Science ®Google Scholar